ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA? | pharmaphorum
AstraZeneca's Imfinzi shows benefits in event-free and overall survival in muscle-invasive bladder cancer, but faces FDA scrutiny over treatment phase contributions. The NIAGARA study results, published in NEJM, suggest a 32% EFS improvement and 25% reduced risk of death. Despite concerns, the FDA approved Imfinzi for lung cancer, raising questions about its decision-making process for NIAGARA.
Reference News
AstraZeneca's Imfinzi shows benefits in event-free and overall survival in muscle-invasive bladder cancer, but faces FDA scrutiny over treatment phase contributions. The NIAGARA study results, published in NEJM, suggest a 32% EFS improvement and 25% reduced risk of death. Despite concerns, the FDA approved Imfinzi for lung cancer, raising questions about its decision-making process for NIAGARA.